AHA reiterates support for most-favored nation drug price rule’s withdrawal
The AHA today restated its strong support for the Centers for Medicare & Medicaid Services’ withdrawal of its Most Favored Nation Model proposed rule. In January, the AHA questioned the proposal’s legality and structure, while expressing deep concerns for the extent to which patients would be negatively impacted by the policy.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services has opened registration for its seventh annual CMS & Health Level Seven International Fast Healthcare…
Headline
The House April 29 passed a Senate-approved budget resolution by a 215-211 vote. Now that the House and Senate have passed…
Headline
President Trump April 30 announced that Nicole Saphier, M.D., has been nominated to be the next U.S. surgeon general. Saphier is a radiologist and…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Chairperson's File
We’re at a watershed moment in health care, which gives us opportunities to strengthen how we serve patients and communities. Health care leaders must help…
Headline
The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is…